Lyon 2020 HFA-ICOS baseline cardiovascular risk before second- or third-generation multi-targeted kinase inhibitors for CML targeting BCR-ABL. Class is very_high, high, medium, or low from published very-high and high factors plus Medium 1/2 points (0–1 low, 2–4 medium, ≥5 high). Caller assigns the 10-year CVD >20% threshold; magent does not compute that score. Not a medical device or treatment order.
| Network | Scheme | Amount | Pay To |
|---|---|---|---|
| Base | exact | $0.005000 USDC | 0x836B...9Ee2 |